Protein biomarker identification in the CSF of patients with CNS lymphoma

Journal of Clinical Oncology

Volumn 26, Issue 1, 2008, Pages 96-105

  Roy, Sushmita ^a   Josephson, S Andrew ^a   Fridlyand, Jane ^a   Karch, Jon ^a   Kadoch, Cigall ^a   Karrim, Juliana ^a   Damon, Lloyd ^a   Treseler, Patrick ^a   Kunwar, Sandeep ^a   Shuman, Marc A ^a   Jones, Ted ^a   Becker, Christopher H ^a   Schulman, Howard ^a   Rubenstein, James L ^a  

^a Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BIOLOGICAL MARKER; RNA;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER DIAGNOSIS; CANCER PATIENT; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEOVASCULARIZATION (PATHOLOGY); NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOID; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 37849044940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.1053     Document Type: Article

References (27)

1. Josephson SA, Papanastassiou AM, Berger MS, et al: The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg 106:72-75, 2007
2. Bernstein M, Berger M: Neuro-Oncology: The Essentials. New York, NY, Thieme Medical Publishers, 2000
3. Hormigo A, Abrey L, Heinemann MH, et al: Ocular presentation of primary central nervous system lymphoma: Diagnosis and treatment. Br J Haematol 126:202-208, 2004
4. Rubenstein JL, Treseler P, O'Brien JM: Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 19:705-717, 2005
5. Abrey LE, Batchelor TT, Ferrari AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
6. Batchelor T, Sorenson AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
7. Chamberlain MC: Neoplastic meningitis: A guide to diagnosis and treatment. Curr Opin Neurol 13:641-648, 2000
8. Ferreri A, Blay J, Reni M, et al: Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266-272, 2003
9. Blay JY, Conroy T, Chevreau C, et al: High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864-871, 1998
10. Antinori A, De Rossi G, Ammassari A, et al: Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 17:554-560, 1999
11. Petricoin EF, Ardekani AM, Hitt BA, et al: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577, 2002
12. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: Comparing data sets from different experiments. Bioinformatics 20:777-785, 2004
13. Hühmer AF, Biringer RG, Amato H, et al: Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. Dis Markers 22:3-26, 2006
14. Dekker LJ, Boogerd W, Stockhammer G, et al: MALDI-TOF spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 4:1341-1349, 2005
15. Rubenstein JL, Fridlyand J, Shen A, et al: Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716-3723, 2006
16. Becker CH, Hastings CS, Norton SM et al: US Patents #6835927 and #7087896: Mass spectrometric quantification of chemical mixture components.
17. Roy SM, Anderle M, Lin H, et al: Differential expression profiling of serum proteins and metabolites for biomarker discovery. Int J Mass Spectrom 238:163-171, 2004
18. Wang W, Zhou H, Lin H, et al: Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal Chem 75:4818-4826, 2003
19. Roy SM, Becker CH: Quantification of proteins and metabolites by mass spectrometry without isotopic labeling, in Sechi S: Methods in Molecular Biology: An Overview of Recent Developments in Quantitative Proteomics Using Mass Spectrometry. Totowa, NJ, Humana Press, 1997
20. Anderle M, Roy S, Lin H, et al: Quantifying reproducibility for differential proteomics: Noise analysis for protein liquid chromatography-mass spectrometry of human serum. Bioinformatics 20: 3575-3582, 2004
21. Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3, 2004
22. Benjamini Y, Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc 57:289-300, 1995
23. Parmigiani G, Garrett-Meyer ES, Anbazhagan R, et al: A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 10:2922-2927, 2004
24. Kaiserman D, Whisstock JC, Bird PI: Mechanisms of serpin dysfunction in disease. Expert Rev Mol Med 8:1-19, 2006
25. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577, 1993
26. Zhang W, Swanson R, Xiong Y, et al: Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: Evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J Biol Chem 281:37302-37310, 2006
27. Cao Y, Lundwall A, Gadaleanu V, et al: Antithrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. Am J Pathol 161:2053-2063, 2002